Study to Investigate the Effects of Krill Oil on Fasting Serum Triglycerides

February 20, 2013 updated by: Aker Biomarine Antarctic AS

A Double-blind, Randomized, Multi-centre, Placebo-controlled Study to Investigate the Effects of Superba(TM) Krill Oil on Fasting Serum Triglycerides

The purpose of this study is to assess the effect of 12 weeks of daily supplementation with Superba(TM) Krill Oil on fasting serum triglyceride levels and omega-3 index in subjects whose habitual fatty fish and seafood intake is low and who have borderline high or high fasting serum triglyceride levels.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Missouri
      • St. Charles, Missouri, United States, 63301
        • Cetero Research
    • North Dakota
      • Fargo, North Dakota, United States, 58104
        • Cetero Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 79 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria(not limited to):

  • General good health with no existing co-morbidities
  • Body mass index (BMI) less than 35 kg/m²
  • Borderline high or high fasting serum triglycerides
  • Clinically normal findings for hematology, clinical chemistry, and urinalysis
  • Be willing to maintain dietary habits and physical activity levels throughout the trial period (next 4 months)
  • Have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less

Exclusion Criteria (not limited to):

  • Familial hypercholesterolemia or severely high total cholesterol levels
  • History or presence of significant cardiovascular disease or co-morbidities
  • Known allergy to crustaceans (shellfish)
  • Bleeding disorders
  • Disturbed absorption due to changes in the gastrointestinal tract
  • Participation in a clinical trial with an investigational product within 30 days before screening
  • Present or recent use (within 3 months of screening or the first screening visit, if applicable) of any medication which is a known lipid modifying agent or any dietary supplements that affect the level of blood cholesterol and triglycerides
  • Current or recent diet, which in the opinion of the Investigator, deviates from a normal diet (e.g., vegetarians may be acceptable, vegans are not acceptable)
  • Female patients that are pregnant or nursing or females of childbearing potential who are not on a method of birth control acceptable to the Investigator during treatment
  • Patients with known coagulopathy or receiving anticoagulant therapy or co-morbidity that would interfere with the study results
  • Frequency of fatty fish and/or seafood consumption is greater than twice per month
  • Present or recent use of any long-chain omega-3 fatty acid supplement
  • Peri-menopausal women or post-menopausal women taking hormone replacement therapy
  • Patients who test positive for human immunodeficiency virus (HIV) or hepatitis B or C
  • Systolic blood pressure greater than 159 mmHg or diastolic blood pressure greater than 99 mmHg or use of anti-hypertensive medication
  • Diabetic subjects
  • Staff of Cetero Research

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in fasting serum triglycerides
Time Frame: Baseline (Day 1) and at Day 85
Baseline (Day 1) and at Day 85

Secondary Outcome Measures

Outcome Measure
Time Frame
Omega-3 index
Time Frame: At Days 1, 42, and 85
At Days 1, 42, and 85

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2011

Primary Completion (ACTUAL)

September 1, 2012

Study Completion (ACTUAL)

September 1, 2012

Study Registration Dates

First Submitted

August 10, 2011

First Submitted That Met QC Criteria

August 11, 2011

First Posted (ESTIMATE)

August 12, 2011

Study Record Updates

Last Update Posted (ESTIMATE)

February 21, 2013

Last Update Submitted That Met QC Criteria

February 20, 2013

Last Verified

February 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • CHSI 1102-16

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Krill Oil

3
Subscribe